These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18536095)

  • 1. Abacavir hypersensitivity.
    Abel S; Paturel L; Cabié A
    N Engl J Med; 2008 Jun; 358(23):2515; author reply 2515-6. PubMed ID: 18536095
    [No Abstract]   [Full Text] [Related]  

  • 2. Abacavir hypersensitivity.
    Vandekerckhove L; Blot S; Vogelaers D
    N Engl J Med; 2008 Jun; 358(23):2514-5; author reply 2515-6. PubMed ID: 18525052
    [No Abstract]   [Full Text] [Related]  

  • 3. Current trends in screening across ethnicities for hypersensitivity to abacavir.
    Rodriguez-Nóvoa S; Soriano V
    Pharmacogenomics; 2008 Oct; 9(10):1531-41. PubMed ID: 18855539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.
    Airo P; Scarsi M; Malagoli A; Carella G; Izzo I; Carosi G; Torti C
    J Acquir Immune Defic Syndr; 2009 Jul; 51(3):361-2. PubMed ID: 19553774
    [No Abstract]   [Full Text] [Related]  

  • 5. HLA-B*5701 Genotyping for Abacavir Prescription: Re-Examination of its Cost-Effectiveness in Singapore.
    Goh KS; Kapoor R; Lee CC; Ng CY; Leong KP
    Ann Acad Med Singap; 2019 Apr; 48(4):133-138. PubMed ID: 31131386
    [No Abstract]   [Full Text] [Related]  

  • 6. HLA-B*5701 screening for hypersensitivity to abacavir.
    Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
    N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Labeling changes for abacavir.
    AIDS Patient Care STDS; 2008 Aug; 22(8):683-4. PubMed ID: 18721055
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacogenomics testing for type B adverse drug reactions to anti-infective drugs: the example of hypersensitivity to abacavir.
    Agundez JA; Esguevillas G; Amo G; Garcia-Martin E
    Recent Pat Antiinfect Drug Discov; 2014; 9(2):151. PubMed ID: 25891395
    [No Abstract]   [Full Text] [Related]  

  • 9. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
    Waters LJ; Mandalia S; Gazzard B; Nelson M
    AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
    Mallal S; Nolan D; Witt C; Masel G; Martin AM; Moore C; Sayer D; Castley A; Mamotte C; Maxwell D; James I; Christiansen FT
    Lancet; 2002 Mar; 359(9308):727-32. PubMed ID: 11888582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uncertainties of routine HLA B*5701 testing in black African HIV cohorts in the UK.
    Sadiq ST; Pakianathan M
    Sex Transm Infect; 2007 Jun; 83(3):181-2. PubMed ID: 17098765
    [No Abstract]   [Full Text] [Related]  

  • 12. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
    Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
    Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir.
    Agbaji OO; Akanbi MO; Otoh I; Agaba PA; Akinsola R; Okolie V; Ugoagwu PO; Babadoko AA; Adediran A; Finomo FO; Abah JO; Muktar HM; Akanmu AS
    Niger Postgrad Med J; 2019; 26(4):195-198. PubMed ID: 31621657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abacavir hypersensitivity reaction predicted by genetic test.
    AIDS Treat News; 2004 Mar; (399):6. PubMed ID: 15199868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.
    Hughes DA; Vilar FJ; Ward CC; Alfirevic A; Park BK; Pirmohamed M
    Pharmacogenetics; 2004 Jun; 14(6):335-42. PubMed ID: 15247625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Mexican Mestizos the HCP5 rs2395029 SNP may be a genetic marker for screening abacavir hypersensitivity.
    Sanchez-Giron F; Carnevale A
    Pharmacogenomics; 2012 Feb; 13(3):251-2. PubMed ID: 22304575
    [No Abstract]   [Full Text] [Related]  

  • 17. Tag SNPs of the ancestral haplotype 57.1 do not substitute HLA-B*57:01 typing for eligibility to abacavir treatment in the Italian population.
    Badulli C; Sestini R; Sbarsi I; Baroncelli M; Pizzochero C; Martinetti M; Porfirio B
    Pharmacogenomics; 2012 Feb; 13(3):247-9. PubMed ID: 22304574
    [No Abstract]   [Full Text] [Related]  

  • 18. Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil.
    Crovella S; Biller L; Santos S; Salustiano A; Brandao L; Guimaraes R; Segat L; Lima Filho JL; Arraes LC
    Clinics (Sao Paulo); 2011; 66(8):1485-8. PubMed ID: 21915505
    [No Abstract]   [Full Text] [Related]  

  • 19. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.
    Hetherington S; Hughes AR; Mosteller M; Shortino D; Baker KL; Spreen W; Lai E; Davies K; Handley A; Dow DJ; Fling ME; Stocum M; Bowman C; Thurmond LM; Roses AD
    Lancet; 2002 Mar; 359(9312):1121-2. PubMed ID: 11943262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HLA-B*5701 and abacavir hypersensitivity reaction].
    Servonnet A; Leclercq E; Delacour H; Ceppa F
    Pathol Biol (Paris); 2010 Dec; 58(6):e95-100. PubMed ID: 19243901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.